Benzinga Psychedelics Capital Conference

As part of the recent so-called “psychedelics renaissance,” numerous celebrities, global leaders and athletes are speaking out about their experiences with these substances. Their stories about the benefits and nuances are now part of an ongoing...

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial Short-acting psychedelics biotech company Small Pharma Inc. DMTTF shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-...

The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll have the opportunity to meet, connect with and learn from some of the most...

This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established Cannabis Capital Conference (CCC), at the Fontainebleau Miami Beach Hotel in Florida....

The upcoming Psychedelics Capital Conference constitutes Benzinga’s effort to provide an exclusive opportunity to meet, connect with and learn from some of the most knowledgeable people in the space.  From companies that perform advanced clinical...

This year is the second edition of what is rapidly becoming the place to be for those interested in or already involved in the psychedelics space: new deals get closed, money gets raised and knowledge is shared at this not-to-be-missed gathering for investors, key...

After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.   And now, after 2022's enormous success, we are holding our second Benzinga...

Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.  Effective as of market opening on March 3, 2023, the upcoming reorganization will consist of...

In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council. The new members include renowned author Amanda Siebert; Revitalist Lifestyle & Wellness (OTCMKTS: RVLWF) CEO Kathryn Walker; Inbodied Life...

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business landscape. To that end, the board is comprised by the leading minds and voices in the space, who share...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Michael Cristalli, Director and Founder of Mystic Holdings Inc. (OTCQX: MSTH), was a guest speaker at Benzinga’s Cannabis Capital Conference on April 21,...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Vahan Ajamian, CPA, CA, CFA and Capital Markets Advisor at High Tide Inc. (NASDAQ: HIDI) was a guest speaker at Benzinga’s Cannabis Capital...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Nenad Yashruti, Business Development Director at Root Sciences, was a guest speaker at Benzinga's Cannabis Capital Conference on April 20, 2022. Root...

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Evan Levine, CEO and Chairman of PsyBio Therapeutics Corp (TSXV: PSYB) (OTCQB: PSYBF), was a guest speaker at Benzinga’s Psychedelic Capital Conference (...

Filament Health (OTCQB: FLHLF) (NEO:FH) is a clinical-stage psychedelic drug development company creating safe, standardized, naturally-derived psychedelic medicines.  CEO and Co-Founder Benjamin Lightburn spoke at the Benzinga Psychedelics Capital Conference, April 19, 2022, about the...